3.09

17.38% -0.65

After Hours: 3.09

Protara Therapeutics Inc (TARA)

Overview News Price History Option Chain Financials Discussions Forecast

Protara Therapeutics Inc stock is currently priced at $3.09, with a 24-hour trading volume of 797.81K. It has seen a -17.38% decreased in the last 24 hours and a +13.19% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $3.71 pivot point. If it approaches the $3.20 support level, significant changes may occur.

Previous Close:

$3.74

Open:

$3.73

24h Volume:

797.81K

Market Cap:

$63.62M

Revenue:

Net Income/Loss:

$-69.17M

P/E Ratio:

-0.5202

EPS:

-5.94

Net Cash Flow:

$-33.93M

1W Performance:

+3.00%

1M Performance:

+13.19%

6M Performance:

+168.70%

1Y Performance:

-8.04%

1D Range:

$2.95

$3.74

52W Range:

$1.04

$5.24

Protara Therapeutics Inc Stock (TARA) Company Profile

Name

Protara Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

646 844 0337

Address

345 Park Avenue South, 3rd Floor, New York, NY

Employee

Twitter

Next Earnings Date

2024-06-07

Latest SEC Filings

TARA's Discussions on Twitter

Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-04-21	Initiated	H.C. Wainwright	Buy
Feb-17-21	Initiated	Oppenheimer	Outperform
Oct-19-20	Initiated	Cowen	Outperform
Jul-29-20	Initiated	Guggenheim	Buy

Protara Therapeutics Inc Stock (TARA) Latest News

Opaleye management sells Protara Therapeutics shares worth over $230k - Investing.com

Investing.com

Opaleye Management Inc. Sells 70,885 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) Stock - MarketBeat

MarketBeat

Protara Therapeutics Inc (TARA) Stock: A Year of Market Movement, Down and Up - The InvestChronicle

The InvestChronicle

TARA Shares Experience Surge in Value – Knox Daily - Knox Daily

Knox Daily

Protara Therapeutics Inc (TARA) Performance and Fundamentals Dashboard tells a completely different story – Sete ... - SETE News

SETE News

Guggenheim gives a Buy recommendation for Protara Therapeutics Inc (TARA) – Knox Daily - Knox Daily

Knox Daily

Protara Therapeutics Inc Stock (TARA) Financials Data

Protara Therapeutics Inc (TARA) Net Income 2024

TARA net income (TTM) was -$69.17 million for the quarter ending September 30, 2023, a -85.87% decrease year-over-year.

Protara Therapeutics Inc (TARA) Cash Flow 2024

TARA recorded a free cash flow (TTM) of -$33.93 million for the quarter ending September 30, 2023, a -19.08% decrease year-over-year.

Protara Therapeutics Inc (TARA) Earnings per Share 2024

TARA earnings per share (TTM) was -$6.13 for the quarter ending September 30, 2023, a -85.20% decline year-over-year.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.